Innocan Pharma Corporation: Innocan Pharma Updates its Progress in the Pre-Clinical Studies of its CBD-Loaded Liposome Platform (LPT)

(3)
Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - August 3, 2021) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), is pleased to issue an update on its cutting-edge pre-clinical studies and on the development progress of its Liposome/CBD delivery platform (LPT). These studies are led by Dr. Ahuva Cern and Prof. Chezy Barenholz of The Hebrew University of Jerusalem.
To date, Innocan completed two pre-clinical trials on animals. The first trial demonstrated no side effects, while the duration of a single intra-muscular injection resulted in the presence of a high level of CBD for at least 3 weeks in the plasma. In the second trial, the researchers observed the effect of CBD in a disease model of the central nervous system, while CBD was detected for a period of over 7 weeks, after 2 injections.

Related Keywords

Jerusalem ,Israel General ,Israel ,Herzliya ,Tel Aviv ,Canada ,Hebrew University ,Yerushalayim ,Canadian ,Iris Bincovich ,Chezy Barenholz ,Innocan Pharma ,Development Company Yissum ,Company Or Innocan ,Innocan Pharma Corporation ,Liposome Research Department ,Lytham Partners ,Innocan Pharma Ltd ,Hebrew University Of Jerusalem ,Alberta Newsfile Corp ,Tel Aviv University ,Yissum Research ,Pharma Corporation ,Ahuva Cern ,Pharma Ltd ,Development Company ,Professor Chezy Barenholz ,Professor Berenholz ,Innocan Israel ,Vice President ,ஏருசலேம் ,இஸ்ரேல் ,தொலைபேசி அவிவ் ,கனடா ,ஹீப்ரு பல்கலைக்கழகம் ,கனடியன் ,ஹீப்ரு பல்கலைக்கழகம் ஆஃப் ஏருசலேம் ,தொலைபேசி அவிவ் பல்கலைக்கழகம் ,பார்மா நிறுவனம் ,பார்மா லிமிடெட் ,வளர்ச்சி நிறுவனம் ,ப்ரொஃபெஸர் பெரன்ஹோல்ஸ் ,துணை ப்ரெஸிடெஂட் ,